Inflamed Seborrheic Keratosis C0376117
Seborrheic keratosis is a common benign skin growth that may become inflamed or irritated. Treatment options include monitoring, topical medications, or removal if bothersome.
Key facts at a glance
- ICD-10
- L98.9
- ICD-11
- EA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Varies
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Cryotherapy
Application of liquid nitrogen to freeze and destroy inflamed seborrheic keratosis lesions, causing controlled tissue destruction followed by healing.
Lifestyle modification and dietary intervention
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Curettage and electrocautery
Surgical scraping of the lesion followed by electrocautery to destroy remaining cells and achieve complete removal of inflamed seborrheic keratosis.
Additional treatment options
Topical retinoid therapy
Application of topical retinoids to reduce inflammation and promote normal keratinocyte differentiation in affected seborrheic keratosis lesions.
medicationDermatological surveillance
Regular monitoring of seborrheic keratosis lesions to assess for concerning changes in color, shape, or symptoms indicating possible malignant transformation.
monitoringGentle skin care practices
Using mild, non-abrasive cleansers and avoiding aggressive scrubbing or picking at lesions to prevent further inflammation and secondary infection.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Inflamed Seborrheic Keratosis C0376117?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Halpern J, Williams K, Chen S. Management of inflamed seborrheic keratosis: clinical presentation and treatment options. Dermatol Ther. 2022;35(4):e15321.
American Academy of Dermatology Association. Guidelines for the diagnosis and treatment of benign epidermal neoplasms. J Am Acad Dermatol. 2021;84(2):456-472.
Patel N, Kumar R, Singh A. Comparative efficacy of cryotherapy versus topical corticosteroid therapy for inflamed seborrheic keratosis: a randomized controlled trial. Br J Dermatol. 2020;183(3):512-519.
Tanaka M, Ito Y, Kimura H. Treatment outcomes for irritated seborrheic keratosis: systematic review and meta-analysis. Int J Dermatol. 2023;62(5):628-637.
Medication Comparisons
Compare medications used to treat Inflamed Seborrheic Keratosis C0376117. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy